Glaucoma News and Research RSS Feed - Glaucoma News and Research

While there are many causes of glaucoma, most cases are associated with increased intraocular pressure. Loss of vision is usually characterized by a gradual reduction in peripheral vision, which can lead to a tunnel vision effect. Glaucoma affects approximately 100 million people globally and is one of the leading causes of blindness in the world today. An estimated three million Americans have this sight-threatening disease. Because it is painless and advances gradually, many people who have glaucoma or elevated IOP have not been diagnosed. If detected and treated early, vision can usually be preserved.
Tablet screening app can improve eye health outcomes in remote, underserved communities

Tablet screening app can improve eye health outcomes in remote, underserved communities

Using a tablet screening app could prove to be an effective method to aid in the effort to reduce the incidence of avoidable blindness in populations at high-risk for glaucoma with limited access to health care, according to a study released today at AAO 2014, the 118th annual meeting of the American Academy of Ophthalmology. [More]
IRIDEX to host Speakers' Forum program at the American Academy of Ophthalmology

IRIDEX to host Speakers' Forum program at the American Academy of Ophthalmology

IRIDEX Corporation (Nasdaq: IRIX) announced today its Speakers' Forum program at the annual meeting of the American Academy of Ophthalmology to be held on October 18 – 21 at McCormick Place in Chicago. [More]
Consultant Live unveils new online sleep disorders educational program for doctors, nurses

Consultant Live unveils new online sleep disorders educational program for doctors, nurses

UBM Medica US announces that Consultant Live a leading online community for primary care clinicians, has unveiled a new online sleep disorders educational program to help doctors and nurses help their patients get a good night's rest. [More]
IRIDEX's new proprietary disposable delivery device granted U.S. patent

IRIDEX's new proprietary disposable delivery device granted U.S. patent

IRIDEX Corporation today announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable delivery device. [More]
Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study. [More]
NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension. [More]
Two genes that cause pediatric glaucoma increases risk of future stroke up to ten times

Two genes that cause pediatric glaucoma increases risk of future stroke up to ten times

Every year in Canada about 50,000 people suffer from a stroke, caused either by the interruption of blood flow or uncontrolled bleeding in the brain. While many environmental risk factors exist, including high blood pressure and smoking, stroke risk is also frequently inherited. Unfortunately, remarkably little is known regarding stroke's genetic basis. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Now, women experiencing morning sickness can benefit from Diclegis drug

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. [More]

Japanese surgeons first to implant InnFocus MicroShunt

InnFocus, Inc. reported today that the first two surgeries have been conducted in Japan in a clinical investigational study using the InnFocus MicroShunt™ glaucoma drainage implant. [More]
BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate™ system in Hong Kong. [More]
Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

The symptoms of dry eye disease include the sensation of grit in the eye, frequently accompanied by itching, burning and visual disturbance. The causes are poorly understood. [More]

Tiny eye implant enables patients to battle glaucoma

For the 2.2 million Americans battling glaucoma, the main course of action for staving off blindness involves weekly visits to eye specialists who monitor - and control - increasing pressure within the eye. [More]
Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders. [More]
DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

Researchers in the United Kingdom have demonstrated that advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study published online today in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]
Study identifies best course of treatment for endophthalmitis

Study identifies best course of treatment for endophthalmitis

The most common cause of endophthalmitis, a potentially blinding condition that can occur after eye trauma, eye surgery, and eye injections, are the well-known staphylococci ("staph") and streptococci ("strep") bacterial strains, according to a study published in the August issue of Ophthalmology and based on a review of 25 years of cases at New York Eye and Ear Infirmary of Mount Sinai (NYEE). [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]
ACAAI offers practical solutions to improve asthma problem in older women

ACAAI offers practical solutions to improve asthma problem in older women

Women over the age of 65 face numerous barriers to good health: an increased risk for obesity, greater struggles against poverty and higher rates of asthma with worse health outcomes. [More]
Researchers create most detailed molecular map for region associated with blinding diseases

Researchers create most detailed molecular map for region associated with blinding diseases

Understanding eye diseases is tricky enough. Knowing what causes them at the molecular level is even more confounding. [More]